Rare cancer patients could gain better access to targeted drugs through new study

NCT ID NCT04814095

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study follows 30 adults with incurable rare cancers or rare genetic changes who are already taking a Health Canada-approved targeted therapy that is not publicly funded. Researchers will track quality of life, survival, and tumor response over time to generate real-world evidence. The goal is to help health agencies decide whether to fund these treatments for broader use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help rare cancer patients access funded targeted therapies by providing real-world evidence of their benefits.

What could go wrong

This is a small, early-stage observational study (30 participants) with no control group, so results may not be conclusive or generalizable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BC Cancer

    RECRUITING

    Vancouver, British Columbia, V5Z4E6, Canada

    Contact Phone: •••-•••-••••